Houston Pharmaceuticals will continue collaborations with both universities and assist in securing grants on behalf of the company.
Leonard Ivins, CEO of Edgeline Holdings, said: “Houston Pharmaceuticals will be instrumental in assisting us through the stage of evaluating and licensing these patents and we believe this relationship will add depth to our company, both in name recognition and industry experience.”